Hyperlipidemia is frequently observed in patients who undergo renal, cardiac, bone marrow, or liver transplantation, and its contribution to the long-term morbidity and survival of patients with organ transplants may be substantial. In the few studies that have focused on the pediatric age group, findings have been inconsistent. The lipoprotein profile of 10 children after liver transplantation was characterized and compared with those in normal population controls and 10 healthy siblings. Hyperlipidemia is frequently observed in patients who undergo renal, cardiac, bone marrow, or liver transplantation. 1-5 Because hyperlipidemia constitutes a predisposing factor to atherosclerosis, its influence on the long-term morbidity and survival of organ transplantation patients could be important. Cyclosporine therapy has been implicated as the major cause of posttransplantation hyperlipidemia, causing not only hypercholesterolemia but also hypertriglyceridemia. Sustained elevations of cholesterol and triglyceride levels have been noted not only posttransplantation, but also in nontransplantation patients receiving cyclosporine. These elevations are noted within 1 to 2 weeks of therapy. 5-7 Although a concomitant decrease in posttransplantation high-density lipoprotein (HDL) cholesterol levels has also been attributed to cyclosporine, 8 in a group of psoriasis patients treated with cyclosporine no consistent changes in HDL cholesterol levels were noted. 6 In contrast to these observations, which attribute the hyperlipidemia mainly to cyclosporine, a recent study in renal transplantation patients noted similar elevations of plasma lipids in patients undergoing either triple therapy with cyclosporine, prednisone, and azathioprine or solely prednisone and azathioprine. 9 Indeed, this was further substantiated in heart transplantation patients in whom total cholesterol levels were significantly higher only in the group of patients requiring corticosteroid maintenance immunosuppression. 10 In adults, posttransplantation hyperlipidemia is probably multifactorial with obesity, renal and liver dysfunction, diabetes mellitus, drug therapy, and a genetic predisposition playing a role. [11][12][13][14][15][16] In posttransplantation children who are otherwise healthy, with normal liver and renal function, these factors do not apply. Furthermore, familial disorders such as familial combined hyperlipidemia, type V dyslipoproteinemia, and dysbetalipoproteinemia usually do not manifest in childhood and are completely expressed only in adulthood, 17 thus eliminating additional confounding factors. Yet few studies have focused on the pediatric age group. Whereas an increase in total cholesterol and triglyceride levels was found in children who had undergone a renal transplantation, 18 only a moderate hypertriglyceridemia, normal total cholesterol, and a decrease in HDL levels were observed in four of six children after a liver transplantation. 19 McDiarmid et al. 20 conducted a longitudinal cohort study in 102 pediatric liver recipient...